A psychedelic drug which causes half-an-hour trips has shown some success in treating depression, early trial results suggest.
Early evidence from a small trial suggests the powerful pharmaceutical-grade hallucinogenic – known as intravenous DMT, or SPL026 – could improve symptoms of moderate to severe depression when used in conjunction with therapy.
According to un-peer reviewed data released by biotechnology company Small Pharma, 14 participants out of 34 were in remission within three months – nine of whom (64%) sustained this up to six months.
